Should I buy or sell Medigene stock right now?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medigene in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" MDGEF shares. View MDGEF analyst ratings or view top-rated stocks .

How have MDGEF shares performed in 2024?

Medigene's stock was trading at $1.50 at the start of the year. Since then, MDGEF shares have increased by 62.0% and is now trading at $2.43. View the best growth stocks for 2024 here .

Are investors shorting Medigene?

Medigene saw a increase in short interest in April. As of April 15th, there was short interest totaling 13,900 shares, an increase of 414.8% from the March 31st total of 2,700 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. View Medigene's Short Interest .

How do I buy shares of Medigene?

Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:MDGEF

Medigene (MDGEF) Stock Price, News & Analysis

→ Elon to Transform U.S. Economy? (From Porter & Company) (Ad)

Free MDGEF Stock Alerts

$2.43

0.00 (0.00%)

(As of 05/8/2024 ET)

Compare

Today's Range: $2.43
▼
$2.43
50-Day Range: $1.50
▼
$2.76
52-Week Range: $1.50
▼
$2.84

Volume: N/A
Average Volume: 600 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Short Interest

Get Medigene alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Medigene

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

MDGEF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDGEF Stock News Headlines

May 2, 2024 | globenewswire.com

Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor

April 26, 2024 | globenewswire.com

Medigene AG reports Financial Results and Business Update for Q1 2024

May 9, 2024 | Porter & Company (Ad)

How Biden has already won 2024

Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.

April 4, 2024 | globenewswire.com

Medigene AG Secures European Patent for its iM-TCR Technology

March 28, 2024 | globenewswire.com

Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update

March 19, 2024 | globenewswire.com

Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

March 18, 2024 | globenewswire.com

Medigene AG to report full year 2023 financial results on March 28, 2024

March 4, 2024 | globenewswire.com

Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo

See More Headlines

Receive MDGEF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:MDGEF
CUSIP: N/A
CIK: N/A
Web: www.medigene.com
Phone: (989) 200-0330
Fax: N/A
Employees: 76
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Selwyn Ho MB BS (Age 53)
MBBS, CEO & Member of Executive Management Board
Comp: $409.36k
Dr. Dolores J. Schendel
Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development
Dr. Ernst-Ludwig Winnacker (Age 83)
Co-Founder & Chairman Scientific Advisory Board
Comp: $21.3k
Dr. Birger Kohlert
Chief Financial Officer
Pamela Keck
Vice President of Investor Relations & Corporate Communications
Dr. Kirsty Crame M.D.
VP and Head of Clinical Research & Development

Key Competitors

View All Competitors

MDGEF Stock Analysis - Frequently Asked Questions

Should I buy or sell Medigene stock right now?: 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medigene in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" MDGEF shares.
View MDGEF analyst ratings or view top-rated stocks.
How have MDGEF shares performed in 2024?: Medigene's stock was trading at $1.50 at the start of the year. Since then, MDGEF shares have increased by 62.0% and is now trading at $2.43.
View the best growth stocks for 2024 here.
Are investors shorting Medigene?: Medigene saw a increase in short interest in April. As of April 15th, there was short interest totaling 13,900 shares, an increase of 414.8% from the March 31st total of 2,700 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.
View Medigene's Short Interest.
How do I buy shares of Medigene?: Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MDGEF) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial